Brexpiprazole versus placebo or other antidepressive agents for treating depression-Reference-Cited by-同舟云学术

Brexpiprazole versus placebo or other antidepressive agents for treating depression

Published:2023-07-28 Issue:7 Volume:2023 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Ralovska Silviya¹,Koychev Ivan²,Marinov Petar¹,Furukawa Toshi A³,Mulsant Benoit⁴⁵,Cipriani Andrea²⁶

Affiliation:

1. Department of Neurology, Psychiatry, Physiotherapy and Rehabilitation, Preventive Medicine, and Public Health; Sofia University "St. Kliment Ohridski"; Sofia Bulgaria

2. Department of Psychiatry; University of Oxford; Oxford UK

3. Department of Health Promotion and Human Behavior; Kyoto University Graduate School of Medicine/School of Public Health; Kyoto Japan

4. Department of Psychiatry; Temerty Faculty of Medicine, University of Toronto; Toronto Canada

5. Centre for Addiction and Mental Health; Toronto Canada

6. Oxford Health NHS Foundation Trust; Oxford UK

Publisher

Wiley

Subject

Pharmacology (medical)

Reference116 articles.

1. Interventional, randomised, double-blind, parallel-group, placebo-controlled, flexible-dose long-term study to evaluate the maintenance of efficacy and safety of 1 to 3 mg/day of brexpiprazole as adjunctive treatment in patients with major depressive disorder with an inadequate response to antidepressant treatment (ADT) www.clinicaltrialsregister.eu/ctr-search/trial/2012-001380-76/results

2. A randomised, placebo-controlled 24-week study evaluating adjunctive brexpiprazole inpatients with major depressive disorder;Bauer;Acta Neuropsychiatrica,2019

3. Brexpiprazole as adjunctive treatment in patients with major depressive disorder with an inadequate response to antidepressant treatment clinicaltrials.gov/ct2/show/study/NCT01838681

4. A phase 3, multicenter, randomized, double-blind, placebo- and active comparator-controlled trial of flexible-dose brexpiprazole (OPC-34712) as adjunctive therapy in the treatment of adults with major depressive disorder, the Delphinus trial www.clinicaltrialsregister.eu/ctr-search/trial/2012-003948-67/results

5. Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study;Hobart;Current Medical Research and Opinion,2018

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk ratios, odds ratios and the risk difference;BMJ Evidence-Based Medicine;2024-07-31

2. How does brexpiprazole compare with placebo for adults with major depressive disorder?;Cochrane Clinical Answers;2024-04-08